Pneumonia treated with imipenem/cilastatin.

Area of Science:

• Infectious Diseases
• Pharmacology
• Critical Care Medicine

Background:

• Bacterial pneumonia, particularly nosocomial infections, presents a significant treatment challenge.
• Patients often have severe underlying conditions and risk factors like intubation and prior antibiotic use.
• Pseudomonas aeruginosa is a common and often resistant pathogen in severe pneumonia.

Purpose of the Study:

• To evaluate the efficacy and tolerance of imipenem/cilastatin for bacterial pneumonia.
• To assess treatment outcomes in patients with both nosocomial and community-acquired pneumonia.
• To identify any limitations or specific pathogen-related challenges with imipenem/cilastatin therapy.

Main Methods:

• An open, prospective, multicenter clinical trial was conducted.
• Forty-three adult patients with bacterial pneumonia were enrolled.
• Clinical outcomes and microbiological data, including pathogen resistance, were analyzed.

Main Results:

• Imipenem/cilastatin achieved a clinical cure rate of 93% in treated patients.
• Treatment failures and superinfections were linked to imipenem-resistant Pseudomonas aeruginosa.
• Six out of ten P. aeruginosa strains developed resistance during therapy.
• Adverse effects were observed in 21% of patients, including one case of pseudomembranous colitis.

Conclusions:

• Imipenem/cilastatin is a safe and highly effective monotherapy for serious lower respiratory tract infections.
• Efficacy is compromised in cases involving Pseudomonas aeruginosa, particularly resistant strains.
• Careful monitoring for resistance is crucial, especially with P. aeruginosa infections.